šŸ“£ Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Using adeno-associated virus gene therapy to treat rare kidney disease

Lead Participant: FREELINE THERAPEUTICS LIMITED

Abstract

Freeline is requesting a change of scope to project number 104902 ā€“ ā€œUsing AAV gene therapy to treat rare kidney diseaseā€ that would redistribute funds to enable critical safety risk mitigation experiments to be performed within the timelines of the grant.

Lead Participant

Project Cost

Grant Offer
FREELINE THERAPEUTICS LIMITED £1,564,444 £ 938,666

Publications

10 25 50